Filana Therapeutics, Inc. (FRA:PX91)
Germany · Delayed Price · Currency is EUR | Market Cap | 52.15M -39.9% |
| Revenue (ttm) | n/a |
| Net Income | -67.56M |
| EPS | -1.40 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.110 |
| Previous Close | 1.124 |
| Day's Range | 1.110 - 1.110 |
| 52-Week Range | 0.989 - 3.902 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Filana Therapeutics
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The... [Read more]
News
Filana Therapeutics Transcript: AGM 2026
The meeting addressed ongoing efforts to resolve the FDA clinical hold on the TSC epilepsy program, introduced new executive team members, and approved all voting proposals, including director reelections and incentive plan amendments. No questions were raised by stockholders.
Filana Therapeutics resumed with Buy at Maxim on rebranding, strategic pivot
As previously reported, Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target The firm is positive on the company’s rebranding and strategic pivot toward…
Filana Therapeutics resumed with a Buy at Maxim
Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tu...
Filana Therapeutics Earnings release: Q1 2026
Filana Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Filana Therapeutics Quarterly report: Q1 2026
Filana Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Filana Therapeutics Slides: Corporate presentation
Filana Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tu...
Filana Therapeutics Proxy statement: Proxy filing
Filana Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Filana Therapeutics publishes simufilam preclinical data
Filana Therapeutics (FLNA) announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a well-accepted mouse model of severe TSC-related epilepsy. T...
Filana Therapeutics management to meet with Maxim
Meeting to be held on March 24-25 hosted by Maxim.
Filana Therapeutics reports Q4 EPS (26c) vs. (57c) last year
“At Filana Therapeutics (FLNA), our name reflects our deep commitment to science and to patients affected by diseases tied to filamin A dysregulation, including TSC-related epilepsy. We are driven by…
Filana Therapeutics sees 1H26 net cash use in operations $14M-$17M
The Company estimates net cash use in operations for first half of 2026 in a range from $14 to $17 million, plus a payment of a $31.25 million estimated loss…
Filana Therapeutics Annual report: Q4 2025
Filana Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Filana Therapeutics Earnings release: Q4 2025
Filana Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Filana Therapeutics Slides: Investor presentation
Filana Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Cassava Sciences says US DOJ has closed investigation into company
Cassava Sciences said on Thursday the U.S. Department of Justice had ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam.
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...
Filana Therapeutics Registration statement: Registration Filing
Filana Therapeutics filed a registration statement on November 13, 2025, providing details about a securities offering with the SEC.
Filana Therapeutics Quarterly report: Q3 2025
Filana Therapeutics has published its Q3 2025 quarterly earnings report on November 12, 2025.
Filana Therapeutics Earnings release: Q3 2025
Filana Therapeutics released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duti...
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ce...
Filana Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
New leadership is steering a strategic pivot to TSC-related epilepsy after Alzheimer's trial setbacks, leveraging strong preclinical results and a robust safety profile. A phase II-A proof-of-concept trial is planned for 2026, with solid financials and broad patent protection.
Filana Therapeutics Quarterly report: Q2 2025
Filana Therapeutics has published its Q2 2025 quarterly earnings report on August 14, 2025.